These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

635 related articles for article (PubMed ID: 25660205)

  • 1. Going beyond the liver: progress and challenges of targeted delivery of siRNA therapeutics.
    Lorenzer C; Dirin M; Winkler AM; Baumann V; Winkler J
    J Control Release; 2015 Apr; 203():1-15. PubMed ID: 25660205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinoma.
    Varshosaz J; Farzan M
    World J Gastroenterol; 2015 Nov; 21(42):12022-41. PubMed ID: 26576089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted Liposomes for siRNA Delivery to Cancer.
    Eloy JO; Petrilli R; Raspantini GL; Lee RJ
    Curr Pharm Des; 2018; 24(23):2664-2672. PubMed ID: 30084323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of In Vivo siRNA Delivery in Cancer Mouse Models.
    Hatakeyama H; Wu SY; Mangala LS; Lopez-Berestein G; Sood AK
    Methods Mol Biol; 2016; 1402():189-197. PubMed ID: 26721492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extrahepatic Targeting of Oligonucleotides with Receptor-Binding Non-Immunoglobulin Scaffold Proteins.
    Winkler J
    Nucleic Acid Ther; 2018 Jun; 28(3):137-145. PubMed ID: 29733239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RNAi-mediated gene knockdown and anti-angiogenic therapy of RCCs using a cyclic RGD-modified liposomal-siRNA system.
    Sakurai Y; Hatakeyama H; Sato Y; Hyodo M; Akita H; Ohga N; Hida K; Harashima H
    J Control Release; 2014 Jan; 173():110-8. PubMed ID: 24120854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strategies for in vivo delivery of siRNAs: recent progress.
    Higuchi Y; Kawakami S; Hashida M
    BioDrugs; 2010 Jun; 24(3):195-205. PubMed ID: 20462284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges.
    Gomes-da-Silva LC; Fonseca NA; Moura V; Pedroso de Lima MC; Simões S; Moreira JN
    Acc Chem Res; 2012 Jul; 45(7):1163-71. PubMed ID: 22568781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ultra-pH-Responsive and Tumor-Penetrating Nanoplatform for Targeted siRNA Delivery with Robust Anti-Cancer Efficacy.
    Xu X; Wu J; Liu Y; Yu M; Zhao L; Zhu X; Bhasin S; Li Q; Ha E; Shi J; Farokhzad OC
    Angew Chem Int Ed Engl; 2016 Jun; 55(25):7091-7094. PubMed ID: 27140428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overcoming the Challenges of siRNA Delivery: Nanoparticle Strategies.
    Shajari N; Mansoori B; Davudian S; Mohammadi A; Baradaran B
    Curr Drug Deliv; 2017; 14(1):36-46. PubMed ID: 27538460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ligand density at the surface of a nanoparticle and different uptake mechanism: two important factors for successful siRNA delivery to liver endothelial cells.
    Akhter A; Hayashi Y; Sakurai Y; Ohga N; Hida K; Harashima H
    Int J Pharm; 2014 Nov; 475(1-2):227-37. PubMed ID: 25169077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic delivery of siRNA by aminated poly(α)glutamate for the treatment of solid tumors.
    Polyak D; Krivitsky A; Scomparin A; Eliyahu S; Kalinski H; Avkin-Nachum S; Satchi-Fainaro R
    J Control Release; 2017 Jul; 257():132-143. PubMed ID: 27356019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficient and targeted delivery of siRNA in vivo.
    Shim MS; Kwon YJ
    FEBS J; 2010 Dec; 277(23):4814-27. PubMed ID: 21078116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physicochemical characterization techniques for lipid based delivery systems for siRNA.
    Kapoor M; Burgess DJ; Patil SD
    Int J Pharm; 2012 May; 427(1):35-57. PubMed ID: 21979250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of RNAi technology for targeted therapy--a track of siRNA based agents to RNAi therapeutics.
    Zhou Y; Zhang C; Liang W
    J Control Release; 2014 Nov; 193():270-81. PubMed ID: 24816071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in the development of siRNA-based therapeutics for cancer.
    Shen Y
    IDrugs; 2008 Aug; 11(8):572-8. PubMed ID: 18683092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanostructured Hyaluronic Acid-based Materials for the Delivery of siRNA.
    Shah K; Chawla S; Gadeval A; Reddy G; Maheshwari R; Kalia K; Tekade RK
    Curr Pharm Des; 2018; 24(23):2678-2691. PubMed ID: 30084325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A designed recombinant fusion protein for targeted delivery of siRNA to the mouse brain.
    Haroon MM; Dar GH; Jeyalakshmi D; Venkatraman U; Saba K; Rangaraj N; Patel AB; Gopal V
    J Control Release; 2016 Apr; 228():120-131. PubMed ID: 26948382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SiRNA delivery: challenges and role of carrier systems.
    Shegokar R; Al Shaal L; Mishra PR
    Pharmazie; 2011 May; 66(5):313-8. PubMed ID: 21699063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current issues of RNAi therapeutics delivery and development.
    Haussecker D
    J Control Release; 2014 Dec; 195():49-54. PubMed ID: 25111131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.